Literature DB >> 29138826

miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma.

Tao He1, Peijie Chen1, Lu Jin1, Jia Hu1, Yifan Li1, Liang Zhou1, Shangqi Yang1, Xiangming Mao1, Yaoting Gui2, Yun Chen3, Yongqing Lai1.   

Abstract

Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system with poor prognosis. microRNAs (miRNAs) are a class of small, non‑coding RNA molecules that serve important roles in biological and pathological processes in several types of human tumors. miRNA (miR)‑660‑5p is dysregulated in many human cancers; however, its role in renal cell carcinoma is currently unclear. In the present study, reverse transcription‑quantitative polymerase chain reaction was performed to examine the expression levels of miR‑660‑5p in RCC tissues and paired normal adjacent tissues (NATs). To determine the function of miR‑660‑5p in RCC cells, wound‑healing and Matrigel assays were performed to determine the effects of miR‑660‑5p on cell migration and invasion, respectively. MTT and Cell Counting kit‑8 assays were performed to determine the effects of miR‑660‑5p on RCC cell proliferation. In addition, flow cytometric analysis was performed to validate the effects of miR‑660‑5p on apoptosis. The results indicated that miR‑660‑5p expression was downregulated in RCC tissues compared with NATs. Restoration of miR‑660‑5p expression using synthetic mimics may suppress cell migration, invasion and proliferation, and induce cell apoptosis, while using synthetic inhibitors may promote cell migration, invasion and proliferation, and suppress cell apoptosis. These results suggested that miR‑660‑5p may serve a tumor suppressive role in RCC tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29138826     DOI: 10.3892/mmr.2017.8052

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  MiR-590-3p regulates cardiomyocyte P19CL6 proliferation, apoptosis and differentiation in vitro by targeting PTPN1 via JNK/STAT/NF-kB pathway.

Authors:  Fanshun Wang; Hongqiang Zhang; Chunsheng Wang
Journal:  Int J Exp Pathol       Date:  2020-10-14       Impact factor: 1.925

2.  Urinary Exosomal MicroRNAs as Potential Non-invasive Biomarkers in Breast Cancer Detection.

Authors:  Marc Hirschfeld; Gerta Rücker; Daniela Weiß; Kai Berner; Andrea Ritter; Markus Jäger; Thalia Erbes
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

3.  Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.

Authors:  Cheng Ai; Guangzhi Ma; Yunfu Deng; Qiangqiang Zheng; Yingcai Gen; Wen Li; Yang Li; Lingling Zu; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2020-02-05       Impact factor: 3.500

4.  circFBXL5 promotes breast cancer progression by sponging miR-660.

Authors:  Huamao Zhou; Guohui Tang; Mi Zhao; Liming Xie; Yuanjie Xie; Zhiwei Zhang; Xiusheng He
Journal:  J Cell Mol Med       Date:  2019-11-15       Impact factor: 5.310

5.  microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors.

Authors:  Julia Oto; Emma Plana; María José Solmoirago; Álvaro Fernández-Pardo; David Hervás; Fernando Cana; Francisco España; Andrea Artoni; Paolo Bucciarelli; Giorgio Carrabba; Silvia Navarro; Giuliana Merati; Pilar Medina
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

6.  Interplay Between MicroRNAs and Targeted Genes in Cellular Homeostasis of Adult Zebrafish (Danio rerio).

Authors:  Ludivine Renaud; Willian A da Silveira; William B Glen; Edward S Hazard; Gary Hardiman
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

7.  Aberrant Expression of miR-592 Is Associated with Prognosis and Progression of Renal Cell Carcinoma.

Authors:  Xianbao Lv; Jingang Shen; Zhen Guo; Lingwei Kong; Guangchun Zhou; Hao Ning
Journal:  Onco Targets Ther       Date:  2019-12-18       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.